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Abstract
Background: Nanomaterials, as a new kind of materials, have been greatly applied in different fields due to their
special properties. With the industrialization of nanostructured materials and increasing public exposure, the
biosafety and potential influences on central nervous system (CNS) have received more attention. Nanosized zinc
oxide (nanoZnO) was suggested to up-regulate neuronal excitability and to induce glutamate release in vitro.
Therefore, we hypothesized nanoparticles of nanoZnO may lead to changes in balance of neurotransmitter or
neuronal excitability of CNS. This study was to investigate if there were effects of nanoZnO on animal model of
depression.
Methods: Male Swiss mice were given lipopolysaccharides (LPS, 100 μg/kg, 100 μg/ml, every other day, 8 times,
i.p.) from weaning to induce depressive-like behaviors. NanoZnO (5.6 mg/kg, 5.6 mg/ml, every other day, 8 times,
i.p.) was given as the interaction. The mouse model was characterized using the methods of open field test, tail
suspension test and forced swim test. Furthermore, the spatial memory was evaluated using Morris water maze
(MWM) and the synaptic plasticity was assessed by measuring the long-term potentiation (LTP) in the perforant
pathway (PP) to dentate gyrus (DG) in vivo.
Results: Results indicated that model mice showed disrupted spatial memory and LTP after LPS injections and the
behavioral and electrophysiological improvements after nanoZnO treatment.
Conclusion: Data suggested that nanoZnO may play some roles in CNS of mental disorders, which could provide
some useful direction on the new drug exploring and clinical researches.
Keywords: Morris water maze, long-term potentiation, depression, hippocampus, nanoparticles zinc oxide
(nanoZnO)
1 Background
Nanotechnologies, which have developed and popular-
ized at an increasing rate, exploit materials and devices
with functionally organization engineered at the nan-
ometer scale. Nanostructured materials, primarily
defined by unique properties and determined interaction
with other disciplines, can interact with biological sys-
tems at basic molecular levels with high specificity.
Making use of this molecular feature, nanodevices can
stimulate and interact with objective cells in certain
ways to induce and maximize desired physiological
responses [1,2]. Presently, nanoscaled materials have
been widely applied in many fields such as medicine,
biotechnology, energy and environmental technology
[1,3-5]. Nanotoxicology and the potential effects on
human body have grown in significance over recent
years fueled by the surge of nanomaterial-based consu-
mer products or building materials in the market. Since
they can pass through biological membranes, nanoparti-
cles have potential toxic effects and significant patholo-
gical consequences in human [3,6-9]. Meanwhile, they’ve
been recognized for their potential biological utility
including biological science and nanomedicine [10,11].
With the industrialization and increasing public expo-
sure, nanosized materials have received more concern
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nervous system (CNS).
ZnO nanoparticles are amongst the most commonly
utilized nanomaterials in consumer products notably on
account of their unique physicochemical properties
[12,13]. Some studies have indicated that nanoZnO
affected functions of different cells or tissues [14,15],
biocompatibility [16] and neural tissue engineering [1,2],
but little was known about the influence on CNS and
CNS related diseases. NanoZnO was suggested to mod-
u l a t es y n a p t i ct r a n s m i s s i o nin vitro [4] and to change
the spatial cognition capability via enhancing long-term
potentiation (LTP) in rats [17]. It’s also suggested that
exposure to nanoZnO led to a genotoxic potential
mediated by lipid peroxidation and oxidative stress [18].
However, nanoZnO has been regarded as a potential
utility in the treatment of cancer and/or autoimmunity
due to its targeting potential [19]. This presented the
potential application in treatment of diseases or some
possible neuroprotection. In addition, our previous stu-
dies indicated that exposure to nanoZnO resulted in
increases in current amplitude and excitability of acutely
isolated rat hippocampal CA3 pyramidal neurons
in vitro [4].
Depression, as a prevalent affective disorder, affects so
many individuals in the course of their lifetimes and has
overwhelming emotional and physical symptoms [20].
A study performed on behalf of the World Health Orga-
nization (WHO) has reported more than half individuals
with depression around the world are not being treated,
and depression would rank the second prevalent cause in
term of illness induced disability by 2020 [21]. However,
there is little information about the pathogenesis of
depressive disorders. Disturbances of neurotransmitters,
ligands and receptors and decoupling of the feedback of
hypothalamic-pituitary-adrenocortical (HPA) systems
with certain impairment of the immune system are sup-
posed to be experienced during depression with anhedo-
nia and orientation alterations towards conscience and
order [22]. It’s suggested that inflammation can induce
abnormities in CNS, such as release of proinflammatory
cytokines, excitatory amino acids and nitroxidative spe-
cies which may be responsible for cognition deficits and
other pathological diseases [23]. Activation of the periph-
eral innate immune system through the administration of
lipopolysaccharide (LPS) induces depressive-like behavior
that can be attenuated by chronic antidepressant admin-
istration. Both clinical reports and research data revealed
that activation of the tryptophan catabolizing enzyme
indoleamine 2, 3-dioxygenase (IDO) was greatly involved.
Through regulating the ratio of plasma kynurenine to
tryptophan, the IDO further alters serotoninergic and
glutamatergic neurotransmission. Alternatively, kynure-
nine, as the major product of peripheral tryptophan
degradation, can be transported into the brain through
blood-brain barrier (BBB) and metabolized to produce
neuroactive glutamatergic compounds, further resulting
in the disorder of transmission system [23]. Accompanied
by cognitive dysfunction, more studies are needed aiming
at insights into the neuropathology of depression and
offering promising alternatives or potential therapeutic
action [24]. In this study, LPS repeated administrations
strongly resemble the core features tested by behavioral
assays, suggesting further examinations of the behavioral
and neurophysiologic changes may shed light on neuro-
biology and treatments of depression.
According to the knowledge above, nanoZnO may play
some potential role in CNS and perhaps during develop-
ment processes of diseases through mediating neuronal
excitability or even release of neurotransmitters. The pre-
sent study was determined to see if there were effects of
nanoZnO on cognitive deficits and long-term potentia-
tion (LTP) changes in mice with depressive-like
behaviors.
2 Methods
2.1 Reagents
Lipopolysaccharide (LPS, L-3129, serotype 0127:B8) was
purchased from Sigma (St. Louis, MO). Before the injec-
tion, the fresh solution was prepared by diluting stock
solution to final dose with sterile endotoxin-free isotonic
saline and was administered intraperitoneally (i.p.). The
stock solution was stored in 4°C.
The particles of nanoZnO in our research were pro-
vided by IntriciQ Materials, Farnborough, Hants GU14
0LX, UK, occurring as white powder which is nearly
insoluble in water but in acids and bases. It was showed
by the transmission electron microscopy (TEM, Tecnai
G 22 0S - T W I N ,F E I ,U S A )i m a g e st h a tn a n o Z n Op a r t i -
cles were with the sizes of 20-80 nm [4]. The stock solu-
tion of nanoZnO was prepared with sterile isotonic
saline. The final concentration suspension was diluted
and dispersed by ultrasonic vibration for 20 min before
every use.
2.2 Animals
All animal care and use were conducted in accordance
with approved institutional animal care procedures. Male
Swiss mice aged 21 days old (weaning) were purchased
from the Laboratory Animal Center, Academy of Military
Medical Science of People’s Liberation Army, and were
reared in standard colony rooms in animal house of
Medical School, Nankai University. Animals had free
access to food and water in a controlled room with con-
stant temperature (24 ± 2°C) and humidity (50-60%) with
a normal light/dark cycle during all phases of experi-
ments. All surgical procedures and behavioral tests took
place during the light phase. Twenty-nine mice were
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group (n = 7, sterile saline, 30 μg/kg, 0.9 g/100 ml, every
other day), LPS group (n = 8, LPS, 100 μg/kg, 100 μg/ml,
every other day), LPS+ nanoZnO group (n = 8, LPS, 100
μg/kg, 100 μg/ml, every other day, nanoZnO, 5.6 mg/kg,
5.6 mg/ml, every other day) and nanoZnO group (n = 8,
nanoZnO, 5.6 mg/kg, 5.6 mg/ml, every other day). Mice
were intraperitoneally injected (i.p.) respectively from
weaning every other day. Injections were totally 8 times
in each group. In the present study, we employed i.p. as
the delivery pathway to avoid surgical damages. In addi-
tion, it’s been clarified that nanoparticles through i.p.
showed a biodistribution in the brain [17,25-28].
All experiments were carried out following the guide-
lines of the Beijing Laboratory Animal Center, and
approved by the Ethical Commission at Nankai University.
2.3 Behavioral experiments
All behavioral experiments were performed on the day
after injections. And all tests were performed in the
dark room of the light cycle.
Forced swim test - the forced swim test (FST) was con-
ducted basically and essentially as described previously
[21,29]. The forced swim apparatus consisted of a cylin-
der container (23 cm in diameter and 31 cm in height)
filled with water (maintained at 23 ± 1°C) to a depth of
15 cm. For each trial, mice were placed into the water
gently and individually for 6 min and then were returned
to their home cage. The water was changed between
tests. During the test, the duration of immobility defined
as an absence of movement necessary to keep the head
a b o v et h ew a t e ro rc l i m bu p w a r d - d i r e c t e da g a i n s tt h e
walls was determined over the last five minutes. Longer
duration of immobility indicated the stronger depressive-
like behavior.
Tail suspension test - we constructed the procedure of
tail suspension test (TST) as described by Steru et al
essentially [21,30,31]. Mice were taken from their home
cage and a small piece of paper adhesive tape was
attached approximately 2 cm from tip of the tail. A sin-
gle hole was punched in the tape and mice were hung
individually for a period of 10 min on a fixed hook.
Keep the mice’s heads about 20 cm above the floor.
Animals would wriggle to avoid this aversive situation
resulting from the suspension and body position. The
time of immobility was determined at activity levels that
excluded all movements and only encompassed immobi-
lity. More time of immobility indicated the stronger
depressive-like behavior.
Open field test - the open field test (OFT) was refer-
enced from procedures of Grønli et al to assess the
effects on locomotor activity. The apparatus consisted of
as q u a r ea r e n a( 4 0c ml o n g×4 5c mw i d e×4 5c m
high) with a certain inner area. The floor was divided
into 16 equal squares by black-colored grids. In brief,
each mouse was placed in one corner of the outer area
and allowed to explore for 5 min. Locomotor activity
was recorded and measured by the number of line
crossings and rearings over a five-min period. Counting
w a sd o n eb yaw e l l - t r a i n e do b s e r v e rw h ow a sb l i n dt o
the treatments. The floor was wiped thoroughly after
each trial. Fewer times of crossing and rearings indi-
cated the stronger anxiety behavior.
2.4 Spatial working memory
All these procedures were performed right following all
behavioral tests.
Mice were trained to learn the position of the invisible
hidden escape platform using a standardized Morris
water maze (MWM) procedure to monitor and evaluate
their hippocampus dependent spatial learning and
memory.
The equipment of MWM consisted of a tank that was
120 cm in diameter and 60 cm in height, which was filled
with water to the depth of 45 cm deep and maintained at
23 ± 1°C by an automatic heater. Black nontoxic ink was
added to make the water opaque. The tank was divided
into four equal quadrants (I, II, III, and IV) by two ima-
ginary perpendicular lines crossing in the center of the
tank. A movable black circular platform (5 cm in dia-
meter) was located in the center of quadrant III which is
supposed to be the target quadrant. The platform sub-
merged 1-2 cm below the water surface so that mouse
could easily climb onto to escape from water. A camera
located above the center of the maze and a computerized
animal tracking system (Ethovision 2.0, Noldus, Wageni-
gen, Netherlands) were used to monitor and relay images.
Data from the trials were collected for off-line analyzing.
The environment was kept lightless and noiseless, main-
taining visual extra-maze clue and furnishment immobile
and minimizing the noise disturbance.
The MWM consisted of two sections: place navigation
and spatial probe. The animals were subjected to training
trials for five consecutive days. Mice were randomly
placed into water facing the pool wall individually from
the preset starting points. The starting location varied
among four equidistant points around the perimeter of
the apparatus. Subsequent starting points proceeded in a
clockwise manner for the ensuing trials. Briefly, the loca-
tion of the platform remained constant and mice were
allowed to swim for 60 s or until they located the plat-
form. Mice that failed to locate the platform within 60 s
were guided manually to the platform and remained for
at least 5 s before returning to their home cage. There
was a 5 min interval among trials.
During the spatial probe, the platform was removed
from the tank. Mice were released into water and
allowed to swim for 60 s individually from the starting
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The time that each subject spent in which the platform
had been located during the training was recorded.
Performance parameters in MWM determined
included latency to the platform, quadrant dwell time,
times of crossing and swimming speed.
2.5 Electrophysiological recordings
After completion of all behavioral assays, the electrophy-
siological recording was measured in vivo. Synaptic
responses were quantified as the field excitatory postsy-
naptic potential (fEPSP) extracellularly recorded in the
perforant pathway (PP) to dentate gyrus (DG) region.
After anesthetized by 5% urethane (0.3 ml/10 g, i.p.), the
mouse was placed in a stereotaxic frame (Narishige,
Japan). At the electrode inputting region of the left side,
the scalp was incised and a small hole was drilled in the
skull using a dental drill. A concentric bipolar stimulating
electrode was slowly implanted into the PP (2.0 mm pos-
terior to the bregma, 1.5 mm lateral to midline, 1.5-2.0
mm ventral below the dura). A monopolar extracellular
stainless steel recording electrode was positioned into
DG region (0.5 mm anterior to the bregma, 3.2 mm lat-
eral to midline, 1.5-2.0 mm ventral below the dura).
During recording, the optimal depths of electrodes were
determined using the electrophysiological criteria.
A stable normalized baseline was recorded for 15 min
after positioning the electrodes. Then a high frequency
stimulus (HFS, 10 pulses at 100 Hz for 2 s repeated
10 times) was delivered at test intensity for induction of
LTP in the DG. The fEPSPs were recorded at 20 kHz
sampling rate (Scope software, PowerLab, AD Instru-
ments, Australia) every 30 s for 60 min. The fEPSPs
were amplified (× 100), filtered at 5-5 kHz, digitized and
recorded using Scope software (Power Lab, AD Instru-
ments, Australia). The initial analysis of data was done
in Clampfit 9.0 (Molecular Devices, Sunnyvale, CA,
USA). The fEPSPs slope was measured as the average
slope from 20% to 80% of the decreasing phase to mea-
sure the synaptic efficacy.
2.6 Statistical analysis
All data were presented as mean ± SEM and analyzed
using SPSS 16.0 and Origin 8.0. Escape latencies and
swimming speeds were compared using repeated mea-
sures ANOVA. Data from spatial probe and LTP
recording were normalized and compared using a one-
way ANOVA, followed by a post hoc pairwise multiple
comparison procedure using the Fisher’sL S Dm e t h o d
if the interaction was significant. The behavioral results
were analyzed with a two-way ANOVA. The probabil-
ity level interpreted as statistically significant was
P < 0.05.
3 Results
3.1 Changes in behavioral tests
To check depressive-like behaviors, the behavioral
assays, including open field test, forced swim test and
tail suspension test which have been used widely to
evaluate this animal model in related researches were
conducted.
Numbers of rearings and crossings in OFT were
counted and compared between groups. The data were
thought to reflect the abilities of exploration and spon-
taneous locomotion. Mice usually struggle to escape
from these situations, interspersed with periods of
immobility that has been interpreted as “behavioral des-
pair” [20,32]. So the time of immobility in FST and in
TST was calculated to glint changes linked to the
depression directly and clinically.
Comparisons revealed that mice of LPS group took
more time to keep immobile in FST than that of control
(122.88 ± 6.10, 83.38 ± 2.82, P < 0.001) and LPS
+nanoZnO group (122.88 ± 6.10, 84.16 ± 3.52, P <
0.001) (as shown in Figure 1.A). Mice of nanoZnO
group took slightly less time to keep immobile than that
of control group (69.88 ± 3.36, 83.38 ± 2.82, P >0 . 0 5 )
at the same time, but there was no difference between
LPS+nanoZnO group and control one (P >0 . 0 5 ) .I n
TST, there were similar results that mice of LPS group
exhibited increased immobility more than that of con-
trol and LPS+nanoZnO groups with significant differ-
ences (197.25 ± 9.50, 108.38 ± 3.04, P < 0.001; 197.25 ±
9.50, 159.16 ± 5.13, P < 0.001) (as shown in Figure 1.B).
In nanoZnO group, mice showed less time than that of
control group (94.38 ± 3.00, 108.38 ± 3.04, P < 0.01).
In OFT, there were significant differences between
LPS group and control group in rearings (22.00 ± 0.97,
40.88 ± 1.58, P < 0.001) but not in crossings (49.16 ±
2.56, 55.00 ± 1.88, P > 0.05) respectively (as shown in
Figure 1.C and 1D). In LPS+nanoZnO group, there was
significant increase in numbers of crossings than that of
LPS group but not the control group (57.14 ± 2.31,
49.125 ± 2.56, P < 0.05; 57.14 ± 2.31, 55 ± 1.88,
P > 0.05). Meanwhile, for the number of rearings, it dis-
played some different results. LPS group showed mark-
edly reduced number of rearings than that of control
group (22 ± 0.98, 40.875 ± 1.58, P < 0.001) but there
was no significant difference between LPS group and
LPS+nanoZnO group (22 ± 0.98, 25,667 ± 1.667, P >
0.05). Also, mice of nanoZnO group displayed signifi-
cantly increased number of rearings than that of control
group (49.25 ± 2.28, 40.875 ± 1.58, P <0 . 0 1 ) .W h i l e
rearing numbers were significantly attenuated in LPS
+nanoZnO group than those of control group. Collec-
tively, these data strongly suggested that activation of
the peripheral innate immune system with LPS
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mice and meanwhile the treatment of nanoZnO resulted
in some improvements in behavioral response and emo-
tional normalization to inescapable stress which might
be sighted.
3.2 Changes of spatial cognition in MWM
To determine whether the administration of LPS effi-
ciently induced depressive-like behaviors in mice with
learning and memory deficits and if the treatment of
nanoZnO particles could reverse or improve these
impairments, the suspension of nanoZnO was injected
in mice intraperitoneally, and changes were analyzed
during the test of MWM.
In place navigation, mice of all groups took decreasing
time over the course of the training to locate the sub-
merged platform indicating that mice could definitely get
and remember the location of the hidden platform
through training and exhibit increasingly efficient
exploratory strategies during the following trials (as
shown in Figure 2.A). Overall repeated ANOVA analyses
showed there were significant differences from day 1 to
day 4 between LPS groups and control group (P <0 . 0 1
on day 1 and P <0 . 0 5o nd a y2 ,3a n d4 ) .A n do nd a y4
and 5, there were also significant differences between
LPS group and LPS+nanoZnO group (P <0 . 0 5 ) .D a t a
also showed that there were no statistical differences
since day 2 until the end of the test (P < 0.05 on day 1).
In spatial probe trial, performances were assessed by
the percentage of time spent in the maze quadrant (quad-
rant dwell time) and mean platform crossings (as shown
in Figure 2.B and Figure 2.C). The ANOVA analyses
showed that mice of LPS group failed to locate the plat-
form in the target quadrant. Percentages of time in the
target quadrant and numbers of platform crossings were
less in LPS group than those of control group (28.121 ±
2.24, 48.9 ± 3.002, P < 0.001; 2 ± 0.408, 4.285 ± 0.333,
P < 0.01), however there were prominent improvements
in LPS+nanoZnO group especially quadrant dwell time
(44.221 ± 3.24, 28.121 ± 2.24, P < 0.01) but not in num-
bers of platform crossings (2.875 ± 0.307, 2 ± 0.408, P >
0.05). Meanwhile, there was no significant difference in
Figure 1 Performances in behavioral assays. Behavioral tests including forced swim test (FST), tail suspension test (TST) and open field test
(OFT). Time of immobility was evaluated in the FST and TST as showed in A and B separately. Numbers of crossings and rearings were counted
in the OFT as showed in C and D. Each data represents mean ± SEM. *P < 0.05, ** P < 0.01, ***P < 0.001.
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between nanoZnO group and control group (55.557 ±
3.939, 48.9 ± 3.002, P > 0.05; 4.857 ± 0.333, 4.285 ±
0.333, P > 0.05).
In addition, the swimming speeds of each group
remained constant throughout the test with no signifi-
cant differences between groups (P >0 . 0 5 ;a ss h o w ni n
Figure 2.D). And the motor ability of animals was not
changed and did not result the difference between
groups. The results suggested that the treatment of
nanoZnO partially reversed the learning and memory
impairment.
3.3 Changes of LTP recording within the PP-DG pathway
Stimulation of PP evoked a basal fEPSPs in DG area and
HFS induced potentiation of synaptic transmission for at
least one hour in LTP recording in vivo.
To further study the mechanisms of nanoZnO parti-
cles, slopes of fEPSPs were normalized and recorded for
15 min as baseline as delineated, and after HFS, slopes
of fEPSPs increased immediately and stabilized above
the baseline level. The ANOVA analysis revealed that
after HFS, LTP was not efficiently induced in mice of
LPS group consistent with the depressed slopes (as
shown in Figure 3.A). Slopes of LTP during the time
course of the last 30 mins were also calculated and
compared for each (as shown in Figure 3.B). It was
found that the fEPSPs slopes were significantly
decreased in LPS group compared with control group
(110.16 ± 5.63, 157.09 ± 6.70, P < 0.001) and LPS
+nanoZnO group (110.16 ± 5.63, 139.78 ± 8.02, P <
0.001), but there was a significant enhancement between
nanoZnO group and control group (206.225 ± 6.06,
157.09 ± 6.70, P < 0.001).
Figure 2 Performances of mice in MWM. Escape latency (A) from the place navigation session, percent of platform quadrant dwell time (B)
and numbers of platform crossings (C) in spatial probe stages and the swimming speed calculated for each training session (D) were presented
as mean ± SEM. There are significant differences when P < 0.05. In Fig.2 (A), *P < 0.05, comparison between LPS+nanoZnO vs. Control;
## P <
0.01, comparison between LPS vs. Control;
Δ P < 0.05,
ΔΔ P < 0.01, comparison between nanoZnO vs. Control; * P < 0.05, comparison between
LPS vs. LPS+nanoZnO.
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It’s reported that nanoengineered materials might be
used as approaches to interact with neurons to stimulate
adhesion and growth and be chemically functionalized
by attaching large varieties of biological molecules to
cellular outer surface (for example, antibodies, peptides
and trophic factors). Different nanosized particles or
materials have been applied as nanoenabled drug-deliv-
ery system. By passing the BBB and translocating to the
blood stream, complex can facilitate certain drugs effi-
ciency and the release of biochemical, providing novel
approaches for transporting therapeutics and targeted
therapy in the treatment of brain cancer, neurodegen-
erative diseases, and used as a sought-after utility in
nanomedicine and neuroscience [1,2,33-36]. In a differ-
ent approach, nonporous silicon coated in electrodes
was observed in PC12 cells to derive precursor cells,
increase neurite outgrowth and decrease glial responses.
Substantia nigra neurons cultured on silicon dioxide
(SiO2) surfaces containing different nanoscale topogra-
phies had differential cell adhesion properties [1]. It’s
concluded that nanomaterials could influence central
nervous system in vitro in a positive way which indi-
cated that nanosized mental materials might act to be
neuroprotective or promotive and the applications were
probably correlated with physical sizes.
It’s been understood that nanostructured zinc oxide
have been widely applied in many aspects due to special
properties and certain levels of biocompatibility. Some
typical distinctive properties of nanoZnO were the cap-
ability of antibacterial [37,38], generation of reactive
oxygen species (ROS) [39,40] and membrane damage
possibly caused by generation of ROS [37,38,40]. They
are consistent with the toxic effects that have recently
received lots of concern. But little was known about its
potential beneficial role either in correlational studies or
in diseases. Previous research in our lab supported that
nanoZnO had effects on acutely isolated rat hippocam-
pal CA3 pyramidal neurons. By enhancing the current
amplitude of INa and IK and shifting neuronal excitabil-
ity, probably mediating neurotransmitter release,
nanoZnO may regulate ionic homeostasis and the
physiological functions of neurons and have potential
influence in CNS which shed light on the possible appli-
cation and treatment in neurotransmitter system disor-
ders in CNS [4]. Meanwhile, understanding the
pathophysiological mechanisms by which inflammation
and depression are linked has wide ranging implications
that spans both disciplines and clinical specialties. As
IDO activation was proposed to mediate a change in
serotoninergic neurotransmission during the develop-
ment of depression, the hypothesis was raised that
nanoZnO may provide some positive benefit to the cog-
nitive impairment or other injuries accompanied by the
depressive-like behaviors. In this study data showed that
nanoZnO improved the behavioral and cognitive deficits
in a mice model of depression, examining by behavioral
assays and electrophysiology respectively.
Open field test, tail suspension test and forced swim
test are usually adopted to detect and evaluate depres-
sive-like behaviors [21,41]. Results obtained in this study
showed that mice of LPS group performed with increased
durations of immobility in TST and FST and less num-
bers of crossings and rearings in OFT. This was asso-
ciated with the decreased exploratory behaviors and
locomotor abilities during depression when animals hap-
pened to be susceptible to hopeless and despair. In con-
cert with previous reports, abilities to explore the
Figure 3 Representative fEPSPs evoked by HFS in PP-DG area in vivo. fEPSPs were continuously recorded and normalized prior to HFS as baseline
and 1 h after HFS as the LTP (A). Values are expressed as percentage of change relative to baseline. Magnitude of LTP, determined as responses
between 30 and 60 min after HFS (B) were represented as the mean ± SEM. There are significant differences in different groups (P <0 . 0 5 ) .
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were severely impaired in LPS group representing the
behavioral and emotional changes which could imitate
and agree with clinical symptoms of depression. Addi-
tionally, mice of LPS+nanoZnO group appeared positive
changes signing benefits resulted from administrations of
nanoZnO.
Morris water maze (MWM) is a well-validated method
for evaluating learning and memory. It can reliably
express hippocampus-related acquisition and the persis-
tence of spatial memory [42,43]. Results in this study
revealed that with the increase of training days, escape
latencies were consistently decreased and there was pro-
minent improvement during the last two days between
mice of LPS+nanoZnO group and LPS group. Meanwhile
there was significant difference between LPS group and
control, indicating the disruption of learning and mem-
ory during depression. This is in accordance with former
reports suggesting that acquisition and retention capaci-
ties were impaired in depression model. Mice in control
group learned quickly and maintained the time of locat-
ing the submerged platform after the first day of training.
The learning ability was mainly reflected by the perfor-
mances in place navigation section. Our data displayed
that escape latency was reduced with the increase of
training between groups, whereas the swimming speed
remained constant suggested that motor ability was not
involved in prolonged latencies. Results also suggested
that treatment of nanoZnO attenuated the impairment of
learning acquisition effectively in LPS group and LPS
+nanoZnO group. Furthermore, the persistence of spatial
memory was mainly reflected through mouse perfor-
mances in spatial probe stage. It’s observed that numbers
of platform crossing and quadrant dwell time were mark-
edly decreased in LPS group. However, the treatment
with nanoZnO ameliorated these defects efficiently.
Some previous reports suggested that chronic neuroin-
flammation induced direct functional impairments of
synaptic plasticity underlying learning and memory pro-
cess [24,44], and over-expressions of cytokines causing
direct neuron injuries [45,46], which were consistent
with the performance in MWM in our study. In brief,
our results indicated that inflammation was sufficient to
induce learning and memory dysfunction and resemble
certain deficits and clinical symptoms, and administra-
tions of nanoZnO could improve the memory ability in
mice with depressive-like behaviors.
Hippocampus, conducting a major function of cogni-
tion and memory, depends on synaptic transmission
properties mainly referring to the neuron network and
synaptic functions [44]. By different means of identifying
and characterizing, LTP usually acts as one functional
index of synaptic plasticity and is one major form of
experience-dependent alteration of excitatory synaptic
transmission. It’s definitely supposed to be the cellular
mechanism underlying memory formation to manifest
the strength of synaptic junctions connecting neurons
and changing with experience [47,48]. Growing evidence
indicates increase in the size of fEPSPs can be observed
after induction by HFS, which is consistent with
enhancement of synaptic plasticity and cognition [49].
Along with function of dentate gyrus (DG) in hippocam-
pus to be understood and its important role in memory
and formation of LTP focused [50-52], we recorded the
LTP in PP-DG area in vivo as a major neurophysiologic
index. Results showed that the normalized slope of the
fEPSPs was seriously abolished in LPS group. And data
obtained from our study were in agreement with the
above result in MWM. Furthermore, it exhibited appar-
ent reinforcement in slopes of fEPSPs in mice of LPS
+nanoZnO group, while in nanoZnO group LTP showed
significant enhancement. According to previous studies,
LTP deficits in LPS group could be connected with many
reasons, such as cytokines [53,54], reactive nitroxidative
species (RNS) [23], or ion channel dysfunction[55]. It was
suggested that cytokines or ROS/RNS could induce direct
neuron injures, decrease the volume of hippocampus [56]
or disturb transmitter system. Results also matched with
previous outcome that nanoZnO enhanced neuron excit-
ability [4,57] and mediated neurotransmitter release, and
even regulated synaptic plasticity. Research in emerging
area of nanotechnology demonstrated that the feasibility
of functionalizing glass attached with inhibitory transmit-
ter GABA (g-amino butyric acid) through particular
molecular interactions in vitro. Applications of nano-
technologies for neuroprotection have focused on limit-
ing the damaging effects of free radicals generated after
injury, which played an important role in neuropatholo-
gical process contributing to CNS ischemia and degen-
erative disorders. Data (not shown) from HELC also
indicated that nanoZnO treatment significantly enhanced
the release of hippocampal transmitter by increasing the
concentration of g-GABA in LPS+nanoZnO group [58].
Additionally, increased prevalence of comorbid depres-
sive symptoms appears during kinds of conditions (such
as aging, obesity) and diseases (such as atherosclerosis,
rheumatoid arthritis), all of which have common chronic
neuroinflammation [21,59,60], undergoing over-expres-
sions of inflammatory cytokine during the peripheral
system. Cytokines modulate release of transmitters, Ca
2+
signal pathway and synaptic function which played an
important role in physiological response and memory
processing besides inflammation and nervous homeosta-
sis [61]. Recent reports from our lab revealed that
through shifting LTP to a higher level than that in the
LPS group, spatial memory and cognition might be
improved to some degree. What’sm o r e ,t h eo v e r -
enhanced LTP in nanoZnO group damaged spatial
Xie et al. Journal of Biomedical Science 2012, 19:14
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Page 8 of 11cognition and capability. This bidirectional effect of
nanoZnO might be explained by disrupting the balance
of stability and flexibility of synaptic plasticity [17]. Cer-
tainly, the effect of nanoZnO on fEPSPs may possibly
through a mechanism that is unrelated to the up-regula-
tion of Na and K channels and still need further investi-
gation to interpret. Briefly, our results suggested
nanoZnO may benefit mice behaviorally and acts to be
neuroprotective in some ways. In the light of other
research, zinc was presumed to act as antidepressive and
shed light on some other possible mechanisms involved
in effects of nanoZnO [62,63].
Interestingly, our data are not strictly consistent prior
reports. Some mentioned that nanoZnO may cause
adverse effects partly due to the generation of reactive oxy-
gen species (ROS) [37,40,64], release of zinc ions
[38,65,66], membrane damage through direct nanoparti-
cle-cell membrane wall interaction or generation of ROS
[37,38,40]. With regard to nervous tissue, data showed
that Neuro-2A cells and human neural cells and fibro-
blasts underwent apoptosis and necrosis when exposed to
nanoZnO [67,68]. A recent study led by Nanyang Techno-
logical University (NTU) has found that nanoZnO could
potentially cause cancer by damaging the DNA which in
turn activates p53, which acts as one of the most impor-
tant tumor suppressors and protects cells from developing
cancer phenotypes [69].
Collectively, the dosage and particle physical diameter
used in this study were proposed to be responsible for
this protection and need to be investigated further.
Some studies considered nanosized particles act in dif-
ferent ways related with particle physical sizes.
5 Conclusion
In summary, this study verified that zinc oxide nanoparti-
cles could ameliorate the behavioral and cognitive
impairment in mice with depressive-like behaviors, prob-
ably through up-regulating neuronal synaptic plasticity
and functions in the area from perforant pathway to the
dentate gyrus. More investigations will be required for a
better understanding of the neuro-effect of nanosized
materials and the underlying mechanisms, which provide
potential therapeutic targets and clinical relevance on
depression. And even more possible function mechan-
isms might be revealed in the further research.
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